Digital Therapeutics Dtx Market
SHARE
PUBLISHED: 2022 ID: SMRC21298
SHARE

Digital Therapeutics (DTx) Market Forecasts to 2028 – Global Analysis By Product and Service Type (Device), Purchase Mode (Individual, Group Purchase Organization), Application (Preventive, Treatment/Care-Related) and By Geography

4.4 (17 reviews)
4.4 (17 reviews)
Published: 2022 ID: SMRC21298

This report covers the impact of COVID-19 on this global market

According to Stratistics MRC, the Global Digital Therapeutics (DTx) Market is accounted for $3.79 billion in 2021 and is expected to reach $22.51 billion by 2028 growing at a CAGR of 29.0% during the forecast period. Digital therapeutics provides evidence-based therapeutic interventions to patients. It is delivered through software programs and devices to prevent, manage, or treat a medical condition. The digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. The design, clinical validation, usability, and data security of digital therapeutics products are all based on advanced technology best practices.

Market Dynamics:

Driver:

Growing incidence of preventable chronic diseases


The high prevalence and incidence rate of chronic diseases is a major concern for healthcare systems across the globe. The treatment of patients with chronic diseases is a significant challenge, as psychosomatic or bio psychic factors very often influence these patients. As chronic diseases are often associated with high levels of uncertainty, patients need to change their behavior as part of a new self-care lifestyle. Furthermore, many chronic disorders and conditions are progressive, and their incidence increases with age. As a result, with significant growth in the global geriatric population, chronic disorders are expected to rise further in the coming years.

Restraint:

Patient data privacy concerns


In many countries, various health apps are deprived of appropriate approvals, leading to concerns of product & data quality, reliability in treatment decisions, patient privacy, security, and the responsible use of data. Digital therapeutics providers have access to patient information and are forbidden from sharing the information with anyone not involved in treating that patient. However, with the integration of data using digital tools, the patient’s data is at risk of being accessed by any healthcare professional not related to the patient’s treatment program. 

Opportunity:

Strategic initiatives by manufacturers


Strategic initiatives practice supports companies undertaking the most important growth or expansion projects. While organizations are normally well-geared to manage the day-to-day aspects of business efficiently, major new strategic initiatives tend to be complex projects with multiple workstreams involved. The team helps clients maintain focus on business-as-usual functions by dexterously supporting the unique and complex task flows that accompany Greenfield integration or post-merger integration.

Threat:

Reluctance among patients to adopt digital therapeutics


Motivating people to use digital therapeutics and building their confidence is a major threat faced by digital therapeutics providers. While older and underserved populations show maximum susceptibility to diseases and the highest occurrence rates, they are the least likely to use digital therapeutics products due to low technology literacy levels. Furthermore, the limit of how much behavioural change will be observed with digital therapeutics is still undefined. The clinical validation and deployment of digital therapeutics are carried out on self-selected or volunteer patients; however, their effect on patients showing resistance is still unknown. Furthermore, it is unknown whether digital therapeutics can be sustained over longer periods; there is little information on total patient retention and long-term outcomes.

The treatment/care-related applications segment is expected to be the largest during the forecast period

The treatment/care-related applications are expected to have the largest share during the forecast period. This segment is attributed to the increasing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

The business-to-business (B2B) segment is expected to have the highest CAGR during the forecast period

The business-to-business (B2B) segment is growing at the highest CAGR in the market. This is attributed to increasing alertness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

Region with largest share:

North America is projected to hold the largest market share due to factors such as the influx of new start-ups, rising investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements.

Region with highest CAGR:

North America is projected to have the highest CAGR during the forecast period. This is attributed to the increase in the geriatric population, rise in incidences of chronic diseases, the surge in demand for wireless & portable systems, and availability of sophisticated reimbursement structure that aims in reducing expenditure.

Key players in the market:

Some of the key players profiled in the Digital Therapeutics (DTx) Market include 2Morrow, Inc., Akili Interactive Labs, Inc., Ayogo Health, BehaVR Inc, Better Therapeutics , Canary Health, Click Therapeutics, CogniFit Ltd., Cognoa, Hinge Health, Livongo, Mango Health, Inc., Mindable Health , Smartpatient , Omada Health, Pear Therapeutics, Propeller Health, Virta Health, Welldoc , and Wellthy Therapeutics.

Key developments:

In April 2021: Welldoc partnered with Dexacom. This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.

In March 2021: Pear Therapeutics partnered with Sprectrum Health Systems. Tufts Health Plan and Spectrum Health Systems announced collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation.

In April 2020: Smartpatient partnered with “Around the Pill’ Solutions for pharmaceutical development. This partnership needs to be done to gain partnered products and developments to gain more customers and expanding the business.

In January 2020: Crossroads Treatment Centers collaborated with Pear Therapeutics to implement the company’s digital platform reSET-O to help patients with opioid abuse and addiction.

Product and Service Types Covered:
• Solutions/Software
• Device
• Service
• Hardware

Sales Channels Covered:
• Business-to-Consumer (B2C)
• Business-to-Business (B2B)

Purchase Modes Covered:
• Individual
• Group Purchase Organization

Applications Covered:
• Preventive Applications
• Treatment/Care-Related Applications

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary       
        
2 Preface     
  
 2.1 Abstract      
 2.2 Stake Holders      
 2.3 Research Scope      
 2.4 Research Methodology      
  2.4.1 Data Mining     
  2.4.2 Data Analysis     
  2.4.3 Data Validation     
  2.4.4 Research Approach     
 2.5 Research Sources      
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions     
        
3 Market Trend Analysis       
 3.1 Introduction      
 3.2 Drivers      
 3.3 Restraints      
 3.4 Opportunities      
 3.5 Threats      
 3.6 Product Analysis      
 3.7 Application Analysis      
 3.8 Emerging Markets      
 3.9 Impact of Covid-19      
        
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry      
        
5 Global Digital Therapeutics (DTx) Market, By Product and Service Type       
 5.1 Introduction      
 5.2 Solutions/Software      
 5.3 Device      
 5.4 Service      
 5.5 Hardware
        
6 Global Digital Therapeutics (DTx) Market, By Sales Channel       
 6.1 Introduction      
 6.2 Business-to-Consumer (B2C)      
  6.2.1 Patients     
  6.2.2 Caregivers     
 6.3 Business-to-Business (B2B)      
  6.3.1 Payers     
  6.3.2 Healthcare Provider     
  6.3.3 Employers     
  6.3.4 Pharmaceutical Companies     
  6.3.5 Other Business-to-Business (B2B)     
        
7 Global Digital Therapeutics (DTx) Market, By Purchase Mode       
 7.1 Introduction      
 7.2 Individual      
 7.3 Group Purchase Organization      
        
8 Global Digital Therapeutics (DTx) Market, By Application       
 8.1 Introduction      
 8.2 Preventive Applications      
  8.2.1 Prediabetes     
  8.2.2 Obesity     
  8.2.3 Nutrition     
  8.2.4 Lifestyle Management     
  8.2.5 Other Preventive Applications     
 8.3 Treatment/Care-Related Applications      
  8.3.1 Diabetes     
  8.3.2 Central Nervous System (CNS) Disorders     
   8.3.2.1 Mental Health Disorder    
   8.3.2.2 Other Central Nervous System (CNS) Disorders    
  8.3.3 Chronic Respiratory Disorders      
  8.3.4 Musculoskeletal Disorders     
  8.3.5 Cardiovascular Diseases     
  8.3.6 Smoking Cessation     
  8.3.7 Medication Adherence     
  8.3.8 Gastrointestinal Disorders     
  8.3.9 Substance Use & Addiction Management     
  8.3.10 Rehabilitation & Patient Care     
  8.3.11 Other Treatment/Care-Related Applications     
        
9 Global Digital Therapeutics (DTx) Market, By Geography       
 9.1 Introduction      
 9.2 North America      
  9.2.1 US     
  9.2.2 Canada     
  9.2.3 Mexico     
 9.3 Europe      
  9.3.1 Germany     
  9.3.2 UK     
  9.3.3 Italy     
  9.3.4 France     
  9.3.5 Spain     
  9.3.6 Rest of Europe     
 9.4 Asia Pacific      
  9.4.1 Japan     
  9.4.2 China     
  9.4.3 India     
  9.4.4 Australia     
  9.4.5 New Zealand     
  9.4.6 South Korea     
  9.4.7 Rest of Asia Pacific     
 9.5 South America      
  9.5.1 Argentina     
  9.5.2 Brazil     
  9.5.3 Chile     
  9.5.4 Rest of South America     
 9.6 Middle East & Africa       
  9.6.1 Saudi Arabia     
  9.6.2 UAE     
  9.6.3 Qatar     
  9.6.4 South Africa     
  9.6.5 Rest of Middle East & Africa     
        
10 Key Developments       
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures      
 10.2 Acquisitions & Mergers      
 10.3 New Product Launch      
 10.4 Expansions      
 10.5 Other Key Strategies      
        
11 Company Profiling       
 11.1 2Morrow, Inc.      
 11.2 Akili Interactive Labs, Inc.      
 11.3 Ayogo Health      
 11.4 BehaVR Inc      
 11.5 Better Therapeutics      
 11.6 Canary Health      
 11.7 Click Therapeutics      
 11.8 CogniFit Ltd.      
 11.9 Cognoa      
 11.10 Hinge Health      
 11.11 Livongo      
 11.12 Mango Health, Inc.      
 11.13 Mindable Health      
 11.14 Smartpatient      
 11.15 Omada Health      
 11.16 Pear Therapeutics      
 11.17 Propeller Health      
 11.18 Virta Health      
 11.19 Welldoc      
 11.20 Wellthy Therapeutics      


List of Tables        
1 Global Digital Therapeutics (DTx) Market Outlook, By Region (2019-2028) ($MN)       
2 Global Digital Therapeutics (DTx) Market Outlook, By Product and Service Type (2019-2028) ($MN)       
3 Global Digital Therapeutics (DTx) Market Outlook, By Solutions/Software (2019-2028) ($MN)       
4 Global Digital Therapeutics (DTx) Market Outlook, By Device (2019-2028) ($MN)       
5 Global Digital Therapeutics (DTx) Market Outlook, By Service (2019-2028) ($MN)       
6 Global Digital Therapeutics (DTx) Market Outlook, By Hardware (2019-2028) ($MN)       
7 Global Digital Therapeutics (DTx) Market Outlook, By Sales Channel (2019-2028) ($MN)       
8 Global Digital Therapeutics (DTx) Market Outlook, By Business-to-Consumer (B2C) (2019-2028) ($MN)       
9 Global Digital Therapeutics (DTx) Market Outlook, By Patients (2019-2028) ($MN)       
10 Global Digital Therapeutics (DTx) Market Outlook, By Caregivers (2019-2028) ($MN)       
11 Global Digital Therapeutics (DTx) Market Outlook, By Business-to-Business (B2B) (2019-2028) ($MN)       
12 Global Digital Therapeutics (DTx) Market Outlook, By Payers (2019-2028) ($MN)       
13 Global Digital Therapeutics (DTx) Market Outlook, By Healthcare Provider (2019-2028) ($MN)       
14 Global Digital Therapeutics (DTx) Market Outlook, By Employers (2019-2028) ($MN)       
15 Global Digital Therapeutics (DTx) Market Outlook, By Pharmaceutical Companies (2019-2028) ($MN)       
16 Global Digital Therapeutics (DTx) Market Outlook, By Other Business-to-Business (B2B) (2019-2028) ($MN)       
17 Global Digital Therapeutics (DTx) Market Outlook, By Purchase Mode (2019-2028) ($MN)       
18 Global Digital Therapeutics (DTx) Market Outlook, By Individual (2019-2028) ($MN)       
19 Global Digital Therapeutics (DTx) Market Outlook, By Group Purchase Organization (2019-2028) ($MN)       
20 Global Digital Therapeutics (DTx) Market Outlook, By Application (2019-2028) ($MN)       
21 Global Digital Therapeutics (DTx) Market Outlook, By Preventive Applications (2019-2028) ($MN)       
22 Global Digital Therapeutics (DTx) Market Outlook, By Prediabetes (2019-2028) ($MN)       
23 Global Digital Therapeutics (DTx) Market Outlook, By Obesity (2019-2028) ($MN)       
24 Global Digital Therapeutics (DTx) Market Outlook, By Nutrition (2019-2028) ($MN)       
25 Global Digital Therapeutics (DTx) Market Outlook, By Lifestyle Management (2019-2028) ($MN)       
26 Global Digital Therapeutics (DTx) Market Outlook, By Other Preventive Applications (2019-2028) ($MN)       
27 Global Digital Therapeutics (DTx) Market Outlook, By Treatment/Care-Related Applications (2019-2028) ($MN)       
28 Global Digital Therapeutics (DTx) Market Outlook, By Diabetes (2019-2028) ($MN)       
29 Global Digital Therapeutics (DTx) Market Outlook, By Central Nervous System (CNS) Disorders (2019-2028) ($MN)       
30 Global Digital Therapeutics (DTx) Market Outlook, By Chronic Respiratory Disorders (2019-2028) ($MN)       
31 Global Digital Therapeutics (DTx) Market Outlook, By Musculoskeletal Disorders (2019-2028) ($MN)       
32 Global Digital Therapeutics (DTx) Market Outlook, By Cardiovascular Diseases (2019-2028) ($MN)       
33 Global Digital Therapeutics (DTx) Market Outlook, By Smoking Cessation (2019-2028) ($MN)       
34 Global Digital Therapeutics (DTx) Market Outlook, By Medication Adherence (2019-2028) ($MN)       
35 Global Digital Therapeutics (DTx) Market Outlook, By Gastrointestinal Disorders (2019-2028) ($MN)       
36 Global Digital Therapeutics (DTx) Market Outlook, By Substance Use & Addiction Management (2019-2028) ($MN)       
37 Global Digital Therapeutics (DTx) Market Outlook, By Rehabilitation & Patient Care (2019-2028) ($MN)       
38 Global Digital Therapeutics (DTx) Market Outlook, By Other Treatment/Care-Related Applications (2019-2028) ($MN)       
        
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.         

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials